跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,369 条关于
“Nonalcoholic Steatohepatitis”
全部
1,369
临床试验
957
药物
22
机构
7
资讯
383
2年前
FDA Approves Rezdiffra (Resmetirom) as First Treatment for NASH with Liver Fibrosis
2年前
Madrigal's Resmetirom Nears Full Approval for NASH Cirrhosis Treatment Following Phase 3 Enrollment Completion
去年
Madrigal Pharmaceuticals Reports Strong Rezdiffra Launch and Provides Corporate Updates
去年
Sagimet Biosciences to Present Denifanstat's Anti-Fibrotic Effects in MASH at MASH-TAG 2025
去年
Oramed Pharmaceuticals Advances Oral Insulin Program with New Phase 3 Trial
去年
FDA Approvals in 2024: NASH Treatment, DMD Therapy, Novel Schizophrenia Drug, and Breast Cancer Advancement
去年
Rezdiffra Demonstrates Improved Quality of Life in NASH Patients with Fibrosis
去年
Madrigal Pharmaceuticals Reports Strong Rezdiffra Launch and Advancement of NASH Cirrhosis Study
去年
FDA Approves Rezdiffra (resmetirom) for NASH with Liver Fibrosis
去年
Madrigal Pharmaceuticals Reports Strong Rezdiffra Launch and Clinical Progress in NASH/MASH
第 1 页，共 39 页
上一页
下一页
